Lung Cancer

Patients with NSCLC harboring KRAS G12C have distinct imaging patterns from patients with other NSCLC genetic mutations.

Despite guideline recommendations, a retrospective study found inadequate biomarker testing rates to direct targeted therapy.

Researchers highlighted promising research into early-stage diagnostics and therapies for NSCLC harboring the KRAS G12C mutation discussed in a review article.

A recent study found that chronic pneumonitis is a rare complication of immune checkpoint inhibitor therapy in patients with NSCLC.

A retrospective analysis demonstrated a 10-point difference in receipt of NGS testing between white and black patients with NSCLC.

Recently released study results report similar chemo-immunotherapy outcomes in KRAS-mutant NSCLC subtypes and poor results in patients with concurrent STK11 and/or KEAP1 mutations.

A recently released retrospective study demonstrates that NSAID use in patients with NSCLC enhances immune checkpoint efficacy.

Subgroup analysis of CodeBreaK 100 trial results found that sotorasib achieved a response in pretreated patients with KRAS^G12C-mutated NSCLC subtypes.

Results from an incidental lung nodule program implemented in a community healthcare system demonstrates this program detects lung cancer in patients who are otherwise ineligible for LDCT screening.